{"brief_title": "Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection", "brief_summary": "This study will evaluate the safety and blood levels of a new pediatric formulation of Famvir in children 1-12 years of age. In Part A, patients will receive a single dose of famciclovir (12.5 mg/kg) to assess pharmacokinetics (PK) and safety. In Part B, patients will receive multiple doses of famciclovir alone or with concomitant oral anti-herpes therapy to assess safety and tolerability. Part B will start only after PK data from Part A had been analyzed.", "condition": ["Herpes Simplex"], "intervention_type": ["Drug"], "intervention_name": ["Famciclovir"], "description": ["Famciclovir sprinkle capsules, 25 mg and 100 mg, using OraSweet\u00ae syrup vehicle"], "arm_group_label": ["Famciclovir, pediatric oral formulation"], "criteria": "Inclusion Criteria: - History or laboratory evidence of herpes simplex infection - Clinical evidence or suspicion of herpes simplex infection Exclusion Criteria: - Patients unable to swallow - Concomitant use of probenecid - Positive pregnancy test Additional protocol-defined inclusion/exclusion criteria may apply. For detailed information on eligibility, please contact the study center nearest to you or call the following numbers: 1-862-778-3544 or 1-434-951-3228", "gender": "All", "minimum_age": "1 Year", "maximum_age": "12 Years", "healthy_volunteers": "No", "keyword": "famciclovir", "mesh_term": ["Herpes Simplex", "Famciclovir", "2-Aminopurine"], "id": "NCT00098059"}